Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Featured study

Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis

18 years - 70 years
All genders
Phase 2
The main purpose of this study is to see if an experimental drug, TRADIPITANT can help people with diabetic or idiopathic gastroparesis who are suffering from nausea.
Learn More
UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

99 years or below
All genders
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
Learn More
UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma

UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma

99 years or below
All genders
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
Learn More
UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

99 years or below
All genders
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
Learn More
UPCC 11917: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

UPCC 11917: A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

99 years or below
All genders
Phase 1
Request for collaborative review: WIRB serving as IRB of record.
Learn More
UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

99 years or below
All genders
TBD
Learn More
UPCC 23217: A Phase 1b/2 Study ofBMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

UPCC 23217: A Phase 1b/2 Study ofBMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

99 years or below
All genders
TBD
Learn More
A Multiple-Site Phase 1/2 Safety and Efficacy Trial of AGTC 402 a Recombinant Adeno-associated Virus Vector Expressing CNGA3 in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

A Multiple-Site Phase 1/2 Safety and Efficacy Trial of AGTC 402 a Recombinant Adeno-associated Virus Vector Expressing CNGA3 in Patients with Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

99 years or below
All genders
Phase 2
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 25% are caused …
Learn More
UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

99 years or below
All genders
TBD
Learn More
Cancer detection rate of Abbreviated (Fast) Breast MRI (AB-MR) after negative Digitial Breast Tomosynthesis in Women status post Conservation Therapy (BCT)

Cancer detection rate of Abbreviated (Fast) Breast MRI (AB-MR) after negative Digitial Breast Tomosynthesis in Women status post Conservation Therapy (BCT)

99 years or below
All genders
Women treated for primary breast cancer who undergo breast conservation therapy face an increased risk of developing a second breast cancer in the ipsilateral and the contralateral breast. Although mammographic screening is recommended annually, the sensitivity of mammography is limited in these patients due to the post treatment changes from …
Learn More
831 - 840 of 1243